CN103936865B - 一种抗血栓融合蛋白及编码该融合蛋白的基因 - Google Patents
一种抗血栓融合蛋白及编码该融合蛋白的基因 Download PDFInfo
- Publication number
- CN103936865B CN103936865B CN201410198379.1A CN201410198379A CN103936865B CN 103936865 B CN103936865 B CN 103936865B CN 201410198379 A CN201410198379 A CN 201410198379A CN 103936865 B CN103936865 B CN 103936865B
- Authority
- CN
- China
- Prior art keywords
- fusion rotein
- antithrombotic
- gene
- encoding
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000004927 fusion Effects 0.000 title claims abstract description 51
- 230000002785 anti-thrombosis Effects 0.000 title claims abstract description 50
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 47
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 14
- 239000002773 nucleotide Substances 0.000 claims abstract description 8
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 230000003042 antagnostic effect Effects 0.000 abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 239000003814 drug Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 229940006607 hirudin Drugs 0.000 description 9
- 208000024172 Cardiovascular disease Diseases 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000001458 anti-acid effect Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 108010007267 Hirudins Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 102000004533 Endonucleases Human genes 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000007625 Hirudins Human genes 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 108010073977 decorsin Proteins 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 101710135378 pH 6 antigen Proteins 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
MTX浓度(mmol/L) | 抗血栓融合蛋白表达量(mg/L·72h) |
0 | 0.1~0.8 |
2×10-8 | 2.5~4.0 |
1×10-7 | 5.0~7.5 |
5×10-7 | 9.0~19.5 |
组别 | n | 给药剂量 | 颈总动脉的堵塞程度(%) |
模型对照组 | 8 | 0μg/kg | 100.00±0.00 |
阳性药对照组1 | 8 | 1650U/kg | 48.68±42.88 |
阳性药对照组2 | 8 | 200μg/kg | 39.28±28.82 |
阳性药对照组3 | 8 | 200μg/kg | 38.43±28.72 |
阳性药对照组4 | 8 | 200μg/kg | 38.75±27.95 |
抗血栓融合蛋白低剂量组 | 8 | 40μg/kg | 33.28±41.11 |
抗血栓融合蛋白中剂量组 | 8 | 200μg/kg | 25.38±39.63 |
抗血栓融合蛋白高剂量组 | 8 | 1mg/kg | 10.89±11.56 |
组别 | 天数 | 心 | 肝 | 脾 | 肺 | 肾 |
对照组 | 14 | 3.59±0.63 | 32.11±2.37 | 4.46±0.90 | 2.71±0.92 | 7.72±0.93 |
实验组 | 14 | 3.48±0.89 | 30.61±3.21 | 4.68±0.73 | 2.92±0.79 | 7.71±0.88 |
对照组 | 30 | 3.61±0.67 | 32.12±2.22 | 4.59±0.88 | 2.92±0.63 | 7.85±0.78 |
实验组 | 30 | 3.53±0.88 | 30.66±3.18 | 4.48±0.61 | 2.95±0.58 | 7.84±0.81 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410198379.1A CN103936865B (zh) | 2014-05-12 | 2014-05-12 | 一种抗血栓融合蛋白及编码该融合蛋白的基因 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410198379.1A CN103936865B (zh) | 2014-05-12 | 2014-05-12 | 一种抗血栓融合蛋白及编码该融合蛋白的基因 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103936865A CN103936865A (zh) | 2014-07-23 |
CN103936865B true CN103936865B (zh) | 2016-04-27 |
Family
ID=51184766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410198379.1A Expired - Fee Related CN103936865B (zh) | 2014-05-12 | 2014-05-12 | 一种抗血栓融合蛋白及编码该融合蛋白的基因 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103936865B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108059672B (zh) * | 2016-11-08 | 2021-06-11 | 中国科学院昆明动物研究所 | 森林山蛭抗血栓肽Sylvestin及其基因和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1245719A (zh) * | 1999-06-30 | 2000-03-01 | 北京大学 | 以无活性胰岛素为骨架的含精氨酸-甘氨酸-天冬氨酸序列的抗栓新药 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10033195A1 (de) * | 2000-07-07 | 2002-03-21 | Aventis Pharma Gmbh | Bifunktionale Fusionsproteine aus Hirudin und TAP |
-
2014
- 2014-05-12 CN CN201410198379.1A patent/CN103936865B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1245719A (zh) * | 1999-06-30 | 2000-03-01 | 北京大学 | 以无活性胰岛素为骨架的含精氨酸-甘氨酸-天冬氨酸序列的抗栓新药 |
Non-Patent Citations (3)
Title |
---|
Deciphering structural and functional roles of disulfide bonds in decorsin;Wu LingZhi et al;《Science China-Chemistry》;20131031;第56卷(第10期);1485-1492 * |
Expression of HNP1cDNA in CHO-dhfr~- cells;刘娟等;《中国人民解放军军医大学学报(英文版)》;20041231;346-349 * |
抗栓形成的融合蛋白在毕赤酵母中表达研究;梁岩;《中国优秀硕士学位论文全文数据库基础科学辑》;20091215;摘要、正文第8页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103936865A (zh) | 2014-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103232973B (zh) | 一种k562细胞扩增激活nk细胞的方法 | |
JP2015526080A (ja) | 植物のマイクロリボ核酸の抽出、製造およびその応用 | |
EP2749568B1 (en) | Cell dna synthesis prevention and cell proliferation inhibition polypeptide and use thereof | |
CN104830822B (zh) | 一种重组人血管舒缓素 | |
CN107022557A (zh) | 新的死亡受体5抗体融合蛋白及其应用 | |
CN102295695A (zh) | 重组人促卵泡激素及其制备 | |
CN105732789A (zh) | 森林山蛭镇痛肽mh2620及其基因和应用 | |
CN103936865B (zh) | 一种抗血栓融合蛋白及编码该融合蛋白的基因 | |
CN111494634A (zh) | 一类治疗慢性疼痛的核酸药物 | |
CN114848610A (zh) | 一种外泌体-vegf-a纳米药物及其制备方法和应用 | |
CN101092452A (zh) | 肿瘤抑素抗血管生成小分子多肽、融合蛋白及两者制备方法 | |
CN101481692B (zh) | 无血清制备重组人类凝血因子ⅸ | |
CN114432332A (zh) | circUTRN在制备治疗心力衰竭药物中的应用、重组载体和治疗心力衰竭的药物 | |
CN110857318B (zh) | 一种抗血栓多肽cystatin-T及其制备方法和应用 | |
CN106676134A (zh) | 从小鼠体内获取ii型固有淋巴细胞的方法及所用载体 | |
CN109609553B (zh) | 提高nk细胞靶向作用力的方法及ccr5基因的应用 | |
CN101444629B (zh) | 一种非注射用的基因治疗药物及其药盒 | |
CN101897953A (zh) | 无创性高穿透性表皮生长因子及其应用 | |
CN101671388B (zh) | 血脑屏障穿透性促红细胞生成素及其应用 | |
CN102924607B (zh) | 用于治疗骨质疏松和血栓的OGP-AcAP5融合蛋白及编码该融合蛋白的核酸 | |
CN102671187B (zh) | Lect2蛋白在制备抗病毒药物中的应用 | |
CN109400692B (zh) | 特异短肽、表达特异短肽的重组间充质干细胞以及它们的应用 | |
CN113355358B (zh) | 一种血清9型重组腺相关病毒复合剂的制备方法及其应用 | |
CN110684803B (zh) | 一种构建骨髓细胞Drp1基因特异性敲减小鼠模型的方法 | |
CN111840327B (zh) | 治疗糖尿病足的间质干细胞制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HARBIN MEDICAL UNIVERSITY Free format text: FORMER OWNER: GUO LING Effective date: 20150122 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 150080 HARBIN, HEILONGJIANG PROVINCE TO: 150081 HARBIN, HEILONGJIANG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150122 Address after: 150081 Nangang City, Heilongjiang Province Health Road, No. 157, Applicant after: Harbin Medical University Address before: 150080 Harbin, Heilongjiang, Nangang District Road, No. 74 Applicant before: Guo Ling |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180125 Address after: 150000 room 2321, No. 368, Changjiang Road, Nangang Central District, Harbin, Heilongjiang Province Patentee after: Harbin Health Health Biotechnology Co., Ltd. Address before: 150081 Nangang City, Heilongjiang Province Health Road, No. 157, Patentee before: Harbin Medical University |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160427 Termination date: 20190512 |